Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-2 adrenergic receptor A subtype (α2A-AR) is a G protein-coupled receptor that plays a key role in regulating sympathetic outflow, neurotransmitter release, and pain. Activation of α2A-AR inhibits adenylyl cyclase activity. It is a therapeutic target for hypertension, sedation, and analgesia. Selective agonists like dexmedetomidine are used clinically, but sedation is a potential side effect. There are species differences in ligand binding profiles between human α2A and rodent α2D.
Gi/o-mediated inhibition of adenylyl cyclase
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-2 Adrenergic Receptor A Subtype (α2A-AR).